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DAbstract
Persistent infections with human papillomaviruses type 18 can result in the development of cervical cancer. HPV18 genomes persist
extrachromosomally in low-grade and precancerous lesions but are always integrated in cervical cancers, and this might contribute to the
progression of HPV18-induced lesions. To address whether integration induces additional changes in host cells, several keratinocyte lines with
wild type and replication-deficient E1 mutant HPV18 (E1C-TTL) genomes were analyzed with high density oligonucleotide arrays. In comparison
to normal keratinocytes, wild type and integrated E1C-TTL HPV18 genomes deregulate the expression of 280 annotated genes. However, the
comparison of wild type with E1C-TTL cell lines did not reveal any significant differences, indicating that neither the loss of E1 nor viral
integration induces additional gene expression changes in low passage HPV18-positive keratinocytes. Half of the deregulated genes have been
described as targets of the p16/Rb/E2F, p53, interferon or NFκB pathways consistent with the functions ascribed to the viral E6 and E7
oncoproteins, but the other half can currently not be ascribed to certain pathways.
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COIntroductionPersistent infections with certain human papillomavirus
types such as HPV16, 18, 31, 33 and others are a necessary risk
factor for the development of cervical cancer (Cogliano et al.,
2005; Munoz et al., 2003). Invasive cancer results from the
progression of precancerous precursor lesions, but the molec-
ular mechanisms contributing to progression of HPV-induced
lesions are not well understood. It has been noted that the viral
genomes are maintained as extrachromosomally replicating
multicopy plasmids in precursor lesions whereas in cervical
cancer cells viral DNA is often found integrated into the host⁎ Corresponding author. Fax: +49 7071 295419.
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doi:10.1016/j.virol.2006.05.030chromosomes (Corden et al., 1999; Cullen et al., 1991; Durst
et al., 1985; Fuchs et al., 1989; Schwarz et al., 1985). Therefore,
the integration of viral DNA may contribute to the progression
of HPV-induced precursor lesions. HPVs integrate randomly
into the host genome, making it rather unlikely that insertional
mutagenesis by HPV contributes to progression (Wentzensen et
al., 2004). On the other hand, it has been noted that integration
occurs in a way that the viral E6 and E7 oncogenes are always
retained and transcribed whereas other parts of the viral genome
such as the E1, E2, E4 and E5 genes are often lost (Corden et al.,
1999; Pater and Pater, 1985; Schwarz et al., 1985; Shirasawa
et al., 1989; Wilczynski et al., 1988). It is well established that
overexpression of HPV gene products derived from the E2 gene
(E2 and E8^E2C proteins) repress the activity of the HPVearly
promoter which is responsible for the expression of the E6 and
E7 oncoproteins (Blachon and Demeret, 2003; Bouvard et al.,
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the negative control of E2 proteins on the expression levels of
E6 and E7 and in this way contribute to malignant progression.
In addition, the E4 genes of HPV16 and 18 have been
demonstrated to have growth suppressive activity in papillo-
mavirus-positive cells, and its removal might also be advanta-
geous for the proliferation of papillomavirus-induced lesions
(Davy et al., 2002; Nakahara et al., 2002). It is not known
whether the viral E1 protein, which is essential for extrachro-
mosomal replication of the viral DNA, also contributes to
changes of the host cell.
Several studies have addressed the molecular consequences
of the integration of HPV16 and HPV33 DNA by comparing
cell lines derived from the HPV16-positive W12 or HPV33-
positive UT-DEC-1 cell lines which differ in the physical state
of viral DNA (Alazawi et al., 2002; Jeon et al., 1995; Ruutu et
al., 2002). This was achieved by either long-term culture or by
selection and expansion of single cell clones (Alazawi et al.,
2002; Jeon et al., 1995; Ruutu et al., 2002). Neither cell lines
with extrachromosomal nor integrated HPV16 DNA were able
to form colonies in soft agar, indicating that events besides
integration may contribute to the development of a malignant
phenotype (Jeon et al., 1995). Comparison of early passage cell
lines with extrachromosomal HPV16 DNA with late passage
cell lines harboring integrated HPV16 DNA detected a number
of changes in cellular gene expression especially the increase of
interferon (IFN)-responsive genes, which was accompanied by
a the loss of the viral mRNA for E2 and an increase in viral E7
protein levels (Alazawi et al., 2002). In a similar approach, the
comparison of early passage cell lines with extrachromosomal
HPV33 DNA with late passage cell lines harboring integrated
HPV33 DNA also detected a number of changes in cellular gene
expression (Ruutu et al., 2002). However, no consistent pattern
of integration-related genes for high risk HPVs has emerged
from these studies.
Studies using cell lines containing either HPV31 genomes,
the HPV16 or HPV18 E6 and E7 oncogenes expressed from
retroviral constructs suggested that the expression of a large
number of cellular genes is deregulated by HPV in keratinocytes
(Chang and Laimins, 2000; Garner-Hamrick et al., 2004; Nees et
al., 2001). Both HPV31 and HPV16E6/E7 downregulate IFN-
responsive genes in keratinocytes (Chang and Laimins, 2000;
Nees et al., 2001). In quiescent HPV16E6/E7 expressing cells
and HPV18 E6/E7-positive cells grown in organotypic cultures,
also the upregulation of proliferation-associated and NFκB-
responsive genes was observed (Garner-Hamrick et al., 2004;
Nees et al., 2001). Taken together, this suggested that changes
induced in the host cell by complete HPV genomes or by only
the oncogenes of HPV16 and 18 can be detected by microarray
technology in tissue culture models and that integration of viral
DNA may add further changes to host cell expression patterns.
To investigate whether integration of HPV DNA has an
immediate effect on host cell transcription, we generated several
stable cell lines by either transfecting replication competent
HPV18 wild type DNA or a replication-deficient HPV18 E1 mt
DNA into keratinocytes of the same donor and assayed for host
cell transcription by microarray technology. We find thatHPV18 wt and E1 mt genomes change the expression of a
large number of genes, including targets of p53, the p16/Rb/
E2F, IFN or NFκB pathways. However, no significant
differences in the gene expression profiles between cell lines
maintaining extrachromosomal HPV18 wt DNA or integrated
HPVE1 mt DNA could be observed.
Results
Generation and characterization of keratinocytes transfected
with wild type and mutant HPV18 DNA
To force the rapid integration of HPV18 DNA into cellular
DNA upon transfection, a replication-deficient HPV18 genome
(HPV18 E1C-TTL) was constructed by inserting a translation
termination linker into the E1 gene which is essential for the
extrachromosomal replication of papillomaviruses (Frattini et
al., 1996). Normal human keratinocytes derived from four
different donors were transfected with wt HPV18 or HPV18
E1C-TTL DNA and pSV2 neo and selected as described
previously (Frattini et al., 1997). G418-resistant clones were
pooled and expanded. At passage 6 to 9, total cellular DNAwas
extracted and analyzed by Southern hybridization (Fig. 1).
DNA was digested with restriction enzymes that either do not
cut the viral genome (BglII) or that recognize three sites in wt
HPV18 DNA (BanII) (Figs. 1A, B). Treating the cellular DNA
derived from HPV18 wt-transfected cells with BglII gave rise to
several bands which correspond to supercoiled, linear, open
circle and concatemeric DNA (Fig. 1A). In contrast to this, in
HPV18 E1C-TTL derived cell lines, only high-molecular
weight DNA species could be detected, indicating a complete
absence of extrachromosomal viral DNA from these cells.
Treatment of the genomic DNAs with BanII revealed that in
both wild type and mutant HPV18 transfected cells full-length
HPV18 genomes are present (Fig. 1B). To quantify the viral
copy numbers in the different cell lines, quantitative real-time
PCR employing a primer/probe pair derived from the E7 region
and for a human single copy gene (DKK1) was used. As can be
seen in Fig. 1C, viral copy numbers ranged from 15 to 250
copies per cell for wt-transfected cell lines and from 3 to 55
copies for E1C-TTL-transfected cell lines. When comparing wt
with E1C-TTL cells derived from the same donor, in all cases,
the viral copy numbers of wild type genomes exceeded the copy
numbers of the E1 mutant cell lines.
Characterization of viral transcription in HPV18 wt and
E1C-TTL cell lines
We next analyzed viral E6/E7 transcription by a quantitative
RNAse protection assay. We used a probe derived from the E6/
E7 region which allows the detection of transcripts spliced at nt.
416 (Fig. 2). The upper panel in Fig. 2 shows that the probe
specifically detects E7 message as the signal is absent from the
yeast RNA used as a negative control. The signal intensities of
the band corresponding to the spliced E7 message obtained in
three independent experiments were quantified by phosphoima-
ging and averaged (Fig. 2, lower panel). As can be seen, the E7
Fig. 1. (A) Southern blot analyses of stable keratinocytes transfected with
HPV18 wt or E1C-TTL (E1) genomes. Total cellular DNA isolated from low
passage keratinocytes established from four different donors (NHK14, 18, 28,
30) was digested with BamHI for which no restriction sites are present in
HPV18 wt DNA. Membranes were hybridized with 32P-labeled random-primed
whole genome HPV18 DNA. A 32P-labeled molecular weight marker (M) and
linearized HPV18 wt DNA at 1 and 10 copies/cell are shown on the left of the
upper panel. The sizes of the marker are indicated on the left. The positions of
concatemeric/integrated (con./int.), open circle (oc), linear (lin.) and closed
covalent circle (ccc) are shown on the right. (B) Total cellular DNAwas digested
with BanII for which three restriction sites at nt. 639, 2179 and 4536 are present
in the HPV18 and analyzed by Southern blot. (C) Quantitative real-time PCR
analysis of the cellular DNAs shown in panels A and B. Numbers are given as
viral copy numbers per two copies of a human single copy gene (DKK1). Error
bars indicate standard deviations obtained from multiple independent
measurements.
Fig. 2. RNAse protection analysis of total RNA isolated from confluent
keratinocytes established from four different donors (NHK14, 18, 28 and 30)
and transfected with HPV18 wt or E1C-TTL (E1) genomes. RNA was
hybridized to an antisense probe spanning the splice donor site at nt. 416. Yeast
RNA served as a negative control. Digested RNA hybrids were separated on a
urea–polyacrylamide gel, dried and exposed to image screens (upper panel). In
the lower panel, averaged quantification of three independent experiments and
the standard deviation is shown. Values are given relative to the E7 RNA levels
of the 28-E1C-TTL cell line which was set to 1. A partial HPV18 genome from
nt. 1 to 1000 is shown below. Indicated are the positions of the E6 and E7 genes
and the positions of the splice donor (SD234) and the splice acceptor (SA415)
within E6. The probe and the protected fragment displayed on top of the figure
are shown.
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When comparing the wt and the E1 mt cell lines derived from
the same donor, wt cells always displayed higher E7 RNA
levels than their E1C-TTL counterparts. Generally, it appeared
that wt cell lines have higher levels of E7 transcripts than E1C-
TTL cell lines.
As the Southern blot data suggested that full-length
genomes are present in the E1 mt cell lines, we performedRT-PCR experiments to determine whether transcripts are
present from which the E2 or the E1^E4 proteins could be
expressed. Using primers positioned at nt. 548 and nt. 4003,
an RT-PCR was performed with RNA isolated from the
different cell lines and also from HeLa cells which are known
to harbor HPV18 genomes missing the E2/E4 region
(Schwarz et al., 1985). RNA from all HPV18-transfected
cell lines but not from HeLa cells gave rise to an RT-PCR
product of approximately 1000 bp in size which is in line
with an E7/E1^E4/E5 transcript using a donor site at nt. 929
and the acceptor site at nt. 3434 (Fig. 3A) (Schneider-Gadicke
and Schwarz, 1986). When using a reverse primer at nt. 3036
which is located upstream of the acceptor site at nt. 3434
RNAs from HPV18-transfected cell lines but not from HeLa
cells gave rise to RT-PCR products of approximately 600 bp
in size which corresponds most likely to a transcript using the
donor site at 929 and an acceptor site at 2779 described (Fig.
3B) (Meyers et al., 1997). Taken together, these data suggest
that the forced integration of HPV18 by disruption of the E1
gene does not abolish transcripts for E2 and E4 transcripts
which is in contrast to the integration of HPV16 genomes in
derivatives of the W12 cell line.
Fig. 3. RT-PCR analysis of spliced HPV18 transcripts. One microgram of total RNA from HPV18-positive cell lines 14-18 wt (1), 14-18 E1 (2), 18-18 wt (3), 18-18 E1
(4), 28-18 wt (5), 28-18 E1 (6), 30-18 wt (7), 30-18 E1 (8), HeLa cells (9) was reverse transcribed and amplified with a sense primer in E7 and antisense primers located
in E4 (A) or E2 (B). As a negative control (nc) water was added to the reaction. Arrows indicate specific amplification products. Molecular weight markers (M) were
used to determine the approximate sizes of the amplification products. (C) A partial HPV18 genome from nt. 1 to 5000 is shown below. Indicated are the positions of
the early genes and the positions of the known splice donor (SD) and acceptor (SA) sites. The locations of the forward (E7) and the reverse (E2, E4) primers are
indicated by arrows.
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normal human keratinocytes reveals no differences between
extrachromosomal and integrated HPV18 genomes
We then characterized global cellular gene expression
changes in HPV18-positive wild type and E1C-TTL mutant
cell lines in comparison to normal human keratinocytes. We
used tissue culture conditions similar to those used for the
analysis of global gene expression changes in HPV16E6/E7-
positive keratinocytes and as in comparison to the analysis of
HPV31-positive keratinocytes also a large number of prolifer-
ation-associated genes appeared to be deregulated (Chang and
Laimins, 2000; Nees et al., 2001). HPV18-positive keratino-
cytes and NHK cells were grown to confluency, growth medium
was changed and 48 h later RNA was isolated. As we were
interested to determine changes that were induced by HPV18
genomes without extensive culturing, cells were analyzed at
low passage (6 to 9 for HPV18-positive keratinocytes and 3 to 6
for NHK cells). RNA was isolated from normal keratinocytes,
the respective HPV18 wt and HPV18 E1C-TTL NHK cells
from the four donors, and subjected to gene expression analysis
using Affymetrix U133A gene chips.
When comparing NHKs with HPV18 wt cells or with
HPV18 E1C-TTL cells, 228 or 200 annotated genes, respec-
tively, were more than 2-fold differentially expressed on the
average (Supplementary Fig. 1). The majority of genes were
deregulated between 2- and 5-fold, and only 25 annotated genes
were deregulated 5- to 28-fold. Of the 228 annotated genes
differentially regulated in HPV18 wt cells, 146 were up- and 82
downregulated. Of the 200 annotated genes differentially
regulated in HPV18 E1C-TTL cells, 140 were up- and 60
down-regulated. An overlap of 155 annotated genes between wt
and E1 mt was observed. This suggested that the differentialexpression of 73 or 45 annotated genes was unique to HPV18
wt or HPV18E1C-TTL cells, respectively. However, when
applying the same parameters used for the comparisons with
NHKs, no differentially expressed genes could be identified
when comparing the HPV18 wt data sets to the HPV18 E1C-
TTL data sets. This indicated that the 118 annotated genes are
also differentially expressed (but to an extent not detected by the
analysis software) in the corresponding wt or E1C-TTL cells or
represent false positives.
Confirmation of selected target genes by real-time RT-PCR and
immunoblotting
To confirm the differential expression of target genes
between NHK and HPV18-positive cells, quantitative real-
time RT-PCR (qRT-PCR) experiments were performed. BIRC3,
CDKN2A (p16), DLG7, DKK1, MCM7, SEPP1 and STK6
were selected which were according to the microarray analysis
regulated between 2.2- (DKK1) and 12-fold (SEPP1), and
additionally BAMBI, KIAA0101 and MAP3K8 were chosen
that were only differentially regulated in either HPV18 wt or
HPV18E1C-TTL cell lines (Supplementary Fig. 1). We were
able to confirm the differential expression of all genes but
MAP3K8 which showed in both wt and E1C-TTL cells
transcript levels similar to NHK cells (Fig. 4A and data not
shown). With the exception of SEPP1 which appeared to be
more strongly deregulated by array analysis than by qRT-PCR,
all other genes were found to be similarly deregulated by both
methods. Furthermore, BAMBI and KIAA0101 were deregu-
lated in HPV18 E1C-TTL lines to a similar extent as in HPV18
wt lines (Fig. 4A). On the other hand, no differential expression
was observed for MAP3K8, in line with our interpretation of the
microarray data that no differences existed between wt and
Fig. 4. (A) Quantitative real-time RT-PCR (qRT) analysis of gene expression levels in HPV18 wt (wt) or HPV18E1-CTTL (E1) cell lines. Expression levels are shown
relative to NHK cells and were calculated with HPRT or PGK1 as a reference gene. The relative expression levels of the averaged microarray data shown in
Supplementary Fig. 1 and the respective standard deviations are also included (array). No significant changes were obtained for KIAA0101 in E1 cell lines and for
TERT in wt or E1C-TTL cell lines using microarrays. (B) Representative semi-quantitative immunoblots of extracts obtained from NHK (18), 18-HPV18 wt- or 18-
HPV18 E1C-TTL-transfected keratinocytes. Chemiluminescence signals of the immunoblots were recorded with a FlourSMax multiimaging system (Biorad) and
analyzed with the Quantity One Software package. The relative changes in protein levels (NHK cells were set to 1) were obtained by dividing the values for the target
protein by the values obtained for α-tubulin which was used as a reference protein.
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expression of several genes from the upregulated E2F and
downregulated IFN clusters at the protein level (CDC2,
CDKN2A/p16, MCM7, STAT1) by semi-quantitative immuno-
blotting using α-tubulin as a reference (Fig. 4B). In all cases, the
signal intensities on the immunoblots correlated well with the
relative changes detected by array technology. The expression of
CDKN2A/p16 was induced at the RNA level 8.8- and 8.4-fold
by wt or E1C-TTL and 12- and 20-fold, respectively, at the
protein level. CDC2 was induced 4.0- (wt) and 3.2-fold (E1C-
TTL) at the RNA and 6.6- (wt) and 9-fold (E1C-TTL) at the
protein level. Also for MCM7 (RNA: wt 2.5/E1 2.3; protein: wt
4.8/E1C-TTL 4.0) and STAT1 (RNA: wt −2.3/E1 −2.3; protein
wt −2.1/E1 −2.1), changes in the RNA levels correlated well
with the changes at the protein levels (Fig. 4B).
It has been reported that HPV16 E6 and E7 induce TERT in
human keratinocytes (Fu et al., 2003; Klingelhutz et al., 1996;
Sprague et al., 2002). However, despite being represented on
the arrays used (probe set ID 207199_at), no induction by
HPV18 was evident. Therefore, we used quantitative real-time
RT-PCR to investigate the expression of TERT in NHKs,
HPV18 wt and HPV18 E1C-TTL-transfected cell lines (Fu
et al., 2003). We observed similar levels in HPV18 wt (15-fold
increase) and HPV18 E1C-TTL cells (18.5-fold increase)
compared to NHKs (Fig. 4A). Based on the expression levels
of other genes investigated, TERT expression levels as
determined by qRT-PCR were very low, making it likely that
the failure to detect TERT expression in these cells by gene
expression arrays is due to its low level of expression, which is
supported by other studies using cDNA arrays (Kelley et al.,
2005). This suggested that HPV18 wt and mt genomes induce
TERT RNA expression in normal human keratinocytes to
similar extents.HPV18 genomes influence the expression p16/Rb/E2F-, p53-,
IFN- and NFκB-regulated genes
Previous reports suggested that the major transcriptional
targets of HPV16E6/E7, HPV18 E6/E7 and HPV31 are
proliferation-associated genes and IFN-regulated genes which
is consistent with some of the activities ascribed to the E6 and E7
oncoproteins (Chang and Laimins, 2000; Garner-Hamrick et al.,
2004; Nees et al., 2001). Therefore, we attempted to group the
differentially regulated genes by comparison with gene array
expression analyses and genome-wide analyses of transcription
factor occupancy obtained for p16/Rb/E2F-, p53-, IFN- and
TNFα/NFκB-regulated genes (Table 1 and Supplementary Fig.
1). These analyses revealed that 85 of the deregulated annotated
genes have been described as being targets of the p16/RB/E2F
pathway (Cam et al., 2004; Ishida et al., 2001; Markey et al.,
2002; Muller et al., 2001; Ren et al., 2002; Semizarov et al.,
2004; Vernell et al., 2003). Furthermore, 12 of the deregulated
annotated genes have been previously described as transcrip-
tional targets for IFN (Chin and Cresswell, 2001; Der et al., 1998;
Heinz et al., 2003; Leaman et al., 2002), with 11 out of 12 having
their expression decreased by HPV18 (Table 1 and Supplemen-
tary Fig. 1). In addition, we identified 19 genes influenced by
HPV18 in keratinocytes that have been previously described as
being regulated by TNFα and NFκB in epidermal keratinocytes
and also other cell types (Table 1) (Banno et al., 2005; Hinata et
al., 2003; Pahl, 1999; Zhang et al., 2005). Of these 19 TNFα/
NFκB-regulated genes, 12 were up- and 7 were downregulated
(Supplementary Fig. 1, Table 1). When comparing the HPV18-
deregulated genes with p53-regulated genes, we noticed an
overlap of 30 genes (Kho et al., 2004; Wei et al., 2006). Of these,
25 were upregulated and 5 were downregulated by HPV18 (Table
1). Interestingly, 22 out of the 30 p53-regulated genes have also
Table 1
Annotated genes were grouped according to their relative change in expression levels compared to NHK cells (Increased = inc. or decreased = dec.) and according to
the regulating pathway Retinoblastoma/E2F (Rb/E2F), NFκB, p53 or interferon (IFN)
Rb/E2F NFκB p53 IFN Miscellaneous
Inc. ASK, ATAD2, BARD1, BIRC5, BRCA1, BUB1,
BUB1B, CCNA2, CCNB1, CCNB2, CCNE2, CDC2,
CDC20, CDC25B, CDC6, CDCA3, CDK2, CDKN3,
CDT1, CENPA, CENPF, CHEK1, CITED2, CKS1B,
CKS2, DHFR, DLG7, DONSON, FANCG, FBXO5,
FEN1, FLJ10858, FZD2, H2AFX, HCAP-G,
HMGB2, HMMR, KIAA0101, KIAA0186, KIF11,
KIF20A, KIF22, KIF23, KIF2C, KIF4A, KNTC2,
KPNA2, MAD2L1, MCM2, MCM3, MCM4,
MCM5, MCM6, MCM7, MELK, MKI67,
MPHOSPH1, MSH6, NEK2, ORC6L, PIR51,
PLK1, PLK4, PMSCL1, PRIM2A, RACGAP1,
RFC3, RFC4, RRM2, SKP2, SMC2L1, SMC4L1,
STK6, TK1, TM4SF1, TMPO, TOP2A, TRIP13,
TTK, TYMS, UBE2C, VRK1, ZWINT
BCL2L1,
BIRC3,
CXCL2,
DUSP5,
FN1,
GADD45B,
IL8, KRT7,
LMNB2, PLAT,
SAA1,
TNFAIP3
CNAP1,
DHRS2,
DUSP5,
NASP,
NMU,
UBE2S
ZFP36L2 ACYP1, AKAP2, APOBEC3B, ASF1B, ASPM,
AURKB, BM039, C10orf3, C1orf38, C20orf172, C3,
CA9, CARHSP1, CDH16, CDKN2A, CHST6, D2S448,
DDX3X, DEPDC1, DKK1, DNAJC6, DUSP10, ECT2,
EMP1, FBN2, FLJ10036, FLJ10156, FLJ10719,
FLJ12973, FLJ20716, FLJ23311, GNE, HMG20B,
HUMGT198A, ITGB4, KIAA0286, KIAA1102,
KIF14, KLIP1, KNTC1, LOC200895, MAP3K8,
MCAM, MDC1, MFAP5, MTB, NS3TP2, NUSAP1,
OIP5, OSR2, PARG1, Pfs2, PKMYT1, PLAUR,
PPAP2C, PRC1, PRSS8, PSIP1, RAMP, RANGAP1,
RNASEH2A, RPL39L, SAA2, SHCBP1, SIL, SLC2A3,
SLC43A3, SLCO4A1, TACSTD1, TFPI2, TIMP3,
TMOD3, TOPK, TPX2, UGT1A10, VIL2, WHSC1
Dec. FGFR2, TUBB BST2,
IFIT3,
IVL,
KRT10,
SERPINB3,
SPINK5,
WNT5A
CA12,
LGALS7,
SEPP1
TLR3,
TRIM22
cig5, G1P2,
HSXIAPAF1,
IFIT1,
IFIT3, MX1,
MX2,
STAT1,
TLR3,
TNFSF10,
TRIM22
AGA, AKR1B10, ALDH2, AP1G1, ASNS, ASS,
ATP9A, BAMBI, BBOX1, BTN3A3, C1orf29,
C20orf42, C9orf95, CALB1, CALML3, CEL, CLCA2,
CLCA4, COL18A1, COX7A1, CXCL14, CYP3A5,
DCT, DEFB1, DSC2, DSG1, EMX2, EPB41L3,
EPHB6, FLJ10904, FLJ20073, FLJ20637, FLJ21511,
FLJ22028, FLJ23233, GJA1, GPNMB, GSTA4, HPGD,
HYAL1, ITM2A, KIAA0220, KIAA0431, KRT1,
KRT15, LAMP3, LEPREL1, LOC339047, LY6D,
MEIS2, MGC4504, MLANA, NDN, NPIP, PCK2, PIR,
POSTN, PPFIBP2, PSAT1, PTPRZ1, RNF128, SATB1,
SERPINB13, SILV, SLC1A4, SLC7A11, SPUVE,
TCN1, TRIB3, TRIM5, TYRP1, UNC5B
Genes deregulated by both p53 and IFN or p53 and NF-kB are indicated. Genes described as being deregulated by both p53 and the Rb/E2F pathway are underlined in
the Rb/E2F column. Genes that could not be grouped into any of these pathways are represented in the column miscellaneous.
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IFN (2 genes) or NFκB (1 gene), indicating indirect effects or
coregulation by different pathways (Table 1). Additionally,
transcription of the CDKN2A (p16/INK4A) gene was found to
be 8-fold increased, in line with CDKN2A/p16 induction being a
common feature of infections with high risk HPVs in vivo and in
vitro (Garner-Hamrick et al., 2004; Klaes et al., 2001; Nees et al.,
2001). Interestingly, more than half of the deregulated genes (149
out of 280 genes) could not be accounted for by the pathways
currently implicated in HR-HPV pathogenesis. Taken together,
these results suggest that HPV18 wt and E1C-TTL genomes
induce changes in keratinocytes that are very similar to those
induced by HPV16E6/E7 oncogenes in quiescent keratinocytes
and overlap in certain aspects with the patterns induced by
HPV18E6/E7 oncogenes in organotypic cultures and by HPV31
in actively dividing keratinocytes (Chang and Laimins, 2000;
Garner-Hamrick et al., 2004; Nees et al., 2001).
Discussion
In this study, we have investigated changes in the keratinocyte
gene expression pattern induced by replicating HPV18 wt or by
the replication-deficient HPV18 E1C-TTL genomes. We found
that a large number of genes are deregulated more than 2-fold by
both HPV18 wt and E1C-TTL genomes compared to normal
keratinocytes. When analyzing the genes influenced by HPV18,we found that 30% of these genes have been reported to be
regulated by Rb/E2F which is consistent with the inactivation of
all Rb family members by E7 proteins (Munger et al., 2001). A
similar but smaller set of cellular genes is induced by HPV16E6/
E7 genes in quiescent keratinocytes, in organotypic cultures by
HPV18E6/E7 and some of them by HPV33 genomes in
logarithmically growing keratinocytes (Garner-Hamrick et al.,
2004; Nees et al., 2001; Ruutu et al., 2002). The second group of
genes represents genes that are regulated by IFN and appear to be
diminished byHPV18. The inhibition of IFN-regulated genes has
been described for human keratinocytes immortalized by HPV31
genomes or by the HPV16E6/E7 oncogenes and is consistent
with the biochemical activities of the HPV16 and 18 E6 and E7
oncoproteins (Barnard and McMillan, 1999; Chang and Laimins,
2000; Li et al., 1999; Nees et al., 2001; Perea et al., 2000; Ronco
et al., 1998). The third set of genes influenced by HPV18 has
been described as being regulated by TNFα and the NFκB
transcription factor family (Banno et al., 2005;Hinata et al., 2003;
Pahl, 1999; Zhang et al., 2005). In line with our observations,
NFκB target genes have been shown to be deregulated by the
HPV16E6/E7 oncogenes in gene expression profiling studies
(Nees et al., 2001). Similar to IFN-regulated genes, this appears to
involve both E6 and E7 proteins (Havard et al., 2002; Huang and
McCance, 2002; Patel et al., 1999; Spitkovsky et al., 2002). We
were also able to identify 30 genes as targets of p53 in line with
the E6-dependent degradation of p53 (Kho et al., 2004; Scheffner
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also reported to be regulated by IFN-, NFκB or p16/Rb/E2F.
Taken together, our gene expression analysis is consistent with
gene expression analyses of keratinocytes expressing the
HPV16E6/E7 or HPV18E6/E7 oncogenes from retroviral
constructs or the complete HPV31 genome and the known
functions of the viral E6 and E7 oncoproteins. However, it
appears that tissue culture conditions influence the outcome as no
E2F target genes were found to be regulated in logarithmically
growing HPV31-positive keratinocytes (Chang and Laimins,
2000). It is also interesting to note that several of the HPV18-
regulated cellular genes found in this study have been described
to be deregulated in vivo by gene expression profiles derived
from HPV-positive and HPV-negative cervical tumor material
using Affymetrix U133A arrays (Wong et al., 2006). This
concerns E2F-regulated genes (CITED2, MCM2, MCM5,
RRM2, TYMS), NFκB-regulated genes (IVL, KRT7, KRT10,
PLAT, SPINK5), one IFN-regulated gene (G1P2) aswell as genes
labeledmiscellaneous by us (CDKN2A, ECT2, RAMP, RPL39L,
DSG1, EPB41L3, FLJ21511, HPGD,KRT1), suggesting that our
tissue culture conditions mimic successfully many aspects of
HPV-induced cancers in vivo (Wong et al., 2006). Interestingly,
we were unable to link half of the regulated genes to the
abovementioned pathways by comparison with published
analyses. This may indicate either that these genes are also yet
not described targets of the known pathways or that HPV18
influences other pathways. Taken together, our data strongly
suggest that the major HR-HPVs target similar pathways which
may explain their similar behavior in vivo. However, we were
unable to detect significant differences between HPV18 wt and
mt cell lines which have only integrated viral genome copies
despite the use of low stringency conditions for the microarray
analysis in order not to overlook potentially deregulated genes.
Our data indicate that the loss of E1 and the resulting integration
of the HPV18 DNA do not lead to dramatic changes in the gene
expression profile in low passage keratinocytes as shown by
direct comparison of microarray data and also by the analysis of
selected genes by qRT-PCT or immunoblotting. A large number
of microarray studies have revealed that subsets of tumors differ
in so called signatures that consist of a large number (∼100) of
genes (Chung et al., 2002). It is therefore unlikely that wt and
E1C-TTL cells differ exclusively in the expression of genes not
present on the array or that were not detected because of low
expression levels such as TERT.
Two studies have addressed the question of whether host cell
gene expression changes during the integration event of high risk
HPV by comparing early with late passage HPV16- or HPV33-
positive cell lines which harbored extrachromosomal viral DNA
at early passages and integrated viral DNA at late passages
(Alazawi et al., 2002; Ruutu et al., 2002). While these
comparisons in both studies identified several deregulated
genes, no consistent patterns emerged. The most obvious effect
in HPV16-positive cells was the upregulation of IFN-regulated
genes during passaging, but this was not observed with HPV33
(Alazawi et al., 2002; Ruutu et al., 2002). However, our data
suggested that no difference between wt and E1C-TTL cells was
evident with respect to IFN-regulated genes (SupplementaryFig. 1 and Fig. 4B). A difference between our study and the study
of Alazawi et al. (2002) is that we were able to detect mRNAs
encoding E2 in all HPV18-positive cell lines irrespective of the
physical state of the viral DNA while the E2 mRNA was lost
early upon passaging of HPV16-positive cells (Alazawi et al.,
2002). Therefore, it could be that some of the identified genes in
HPV16-positive W12 cells represent cellular E2 target genes as
E2 functions as a bona fide transcriptional regulator (Blachon
and Demeret, 2003).
Furthermore, while our approach was designed to detect
donor-independent changes caused by integration of HPV18,
studies with HPV16 and 33 were using cell clones derived from
a single donor cell line (Alazawi et al., 2002; Ruutu et al., 2002).
Thus, it may also be that integration causes donor-specific
changes which would have gone unnoticed in our experimental
setup. Interestingly, similar quantitative changes are induced by
wt and mt HPV18 genomes despite differences in viral copy
numbers and in E6/E7 transcript levels. When the amount of
spliced E7 RNA (Fig. 2) is corrected for the viral copy number
(Fig. 1C), integrated genomes produce 1.9- to 10-fold more
RNA than episomal copies in three of the cell line pairs whereas
in one case episomal copies are approximately 4-fold more
active than integrated copies, indicating that integration does
not always deregulate viral transcription. However, this might
be related to E2 protein levels. Certainly, the role of E2 and
especially the amounts of protein present in different types of
lesions induced by different HPVs need to be addressed in the
future to clarify its role during progression.
In vivo studies revealed that integration of viral DNA cannot
be observed in CIN1 but appears first in CIN2/3 lesions and is
found in the majority of CIS, indicating that integration is a late
event during progression (Cullen et al., 1991; Hudelist et al.,
2004; Pirami et al., 1997). Therefore, we favor a model in which
cellular changes lead to integration of viral DNA which by
selection and outgrowth (e.g. loss of E2) cause additional changes
that might also be more pronounced in certain patients as
suggested by the long-term tissue culture studies of HPV16 and
33 (Alazawi et al., 2002; Jeon et al., 1995; Ruutu et al., 2002).
Materials and methods
Plasmids
The wild type HPV18 genome was cloned as an EcoRI
fragment into the pGEMII plasmid. The HPV18 E1C-TTL
mutant genome was constructed by inserting a double stranded
oligonucleotide (5′-GACTAGTTAACGTGA-3′) into the
unique HpaI site (HPV18 nt. 2472) of pGEMII-HPV18 which
introduces a translation termination signal into the E1
replication gene. Plasmid pDrive-HPV18-214–567 was gener-
ated by cloning a PCR product encompassing HPV18 nt. 214 to
567 into pDrive (Qiagen).
Cell culture
Normal human foreskin keratinocytes (NHK) and HPV18-
positive keratinocyte cell lines were cocultured with Mitomycin-
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5% fetal bovine serum as described (Frattini et al., 1996). The
generation of HPV18-positive cell lines including the preparation
of viral DNA, lipofection into NHKs, selection with G418 and
expansion of pooled cultures was performed as described (Frattini
et al., 1997). All materials (nucleic acids, cell extracts) from
HPV18-positive keratinocytes and NHKs were isolated from low
passage cells (p3–5 for NHKs and p5–9 for HPV18-positive
cells) that were treated identically: cells were grown to
confluency, the growth medium was changed and cells harvested
46 to 48 h later to prepare nucleic acids or protein extracts.
Southern blotting
Genomic DNA was isolated by proteinase K digestion,
phenol extraction and ethanol precipitation as described
(Stubenrauch et al., 2000). Detection of HPV18 DNA by
Southern blotting was done essentially as described (Stuben-
rauch et al., 2000).
PCR
Real-time PCR was performed on an SDS5700 system
(Applied Biosystems) with either qPCR Mastermix (Euro-
gentec) for Taqman probes or with qPCR Mastermix for
SYBR Green I (Eurogentec) reagents in triplicates. To
determine viral copy numbers in HPV18-positive cells,
equal amounts of total DNA (30 ng) were amplified with an
HPV18-specific primer/probe set (HPV18E7 548F 5′-
ACGACTCCAACGACGCAGAG-3′; HPV18E7 655R 5′-
CGGAATTTCATTTTGGGGCT-3′; HPV18E7 594T Fam-
ATGGACCTAAGGCAACATTGCAAGACATTGTAT-Tamra)
and a human single copy gene (DKK1) primer/probe set
(hDKK1-F 5′-GAGTTCAAGGTGGCGCTCA-3′; hDKK1-R
5′-GAAAATGACCGTCA;CTTTGCAA-3′; hDKK1-P Fam-
CGCCGCTACCATCGCGACAAAG-Tamra). Absolute copy
numbers were obtained by comparison with dilutions of
plasmids harboring HPV18 or a DKK1 fragment. To
determine relative transcript amounts, cDNA was synthesized
from total RNA (1–5 μg) with the SuperScript II First-Strand
Synthesis kit (Invitrogen) and random hexamer primers
according to the manufacturer's recommendation. Each real-
time PCR reaction received 30 ng of cDNA. Transcripts of
cellular genes were detected with the following primer sets:
BAMBI (Qiagen, Quantitect QT00091329); BIRC3 (Applied
Biosystems, Assays on demand Hs00154109_m1); CDKN2A
(Qiagen, Quantitect QT00089964); DEFB1 (DEFB1 201F
5′-TCTATTCTGCCTGCCCGATCT-3′; DEFB1 288R
5′-TGGTCACTCCCAGCTCACTTG-3′); DLG7 (DLG7 for
5′-CTTCTTGATTCACCAGGTCTAAACTG-3′; DLG7 rev
5′-ATCAGGTTACCACCAAAAGAAATGT-3′); HPRT
(HPRT 499F 5′-CACTGGCAAAACAATGCAGACT-3′;
HPRT 589R 5′-GGTCCTTTTCACCAGCAAGCTT-3′);
KIAA0101 (KIAA0101 for 5′-GCATTGTTTGGTTTCTTT-
TACCAA-3′; KIAA0101 rev 5′-GGCAGCAGTACAA-
CAATCTAAGCA-3′); MAP3K8 (Applied Biosystems,
Assays on demand Hs00178297_m1); MCM7 (MCM71553F 5′-TCCCGGTTTGACCTCCTCT-3′; MCM7 1652R
5′-GCCGGCTGTGCTGGTG-3′); PGK1 (Applied Biosys-
tems, Assays on demand Hs99999906_m1); STK6 (STK6
322F 5′-TCTCATCATGCATCCGACCTT-3′; STK6 446R 5′-
TGGAGAGCTTAAAATTGCAGATTTT-3′); SEPP1 (SEPP1
194F 5′-AGGCATCTAAATTAGAAGACCTGCG-3′; SEPP1
475R 5′-ATGGGAAAGTTAGGAAGGAAAAA-3′); TERT
(hTERT-F 5′-TGACACCTCACCTCACCCAC-3′; hTERT-R
5′-CACTGTCTTCCGCAAGTTCAC-3′; hTERT-T Fam-
ACCCTGGTCCGAGGTGTCCCTGAG-Tamra) (Fu et al.,
2003). Relative transcript amounts were calculated by the
ΔΔCT method (Applied Biosystems) with HPRT or PGK1 as
a reference gene.
Qualitative one step RT-PCR was performed with 1 μg of
total RNA, primers HPV18E7 548F, HPV18 E2 3076R
(5′-CAAGGCCTTGTAGGGCCATT-3′) or HPV18E4 4003R
(5′-CCATGCATACGCACACATACAG-3′) and the Access
RT-PCR system (Promega) according to the manufacturer's
recommendations.
RNAse protection analyses
Total RNA was isolated from confluent keratinocytes with
TRIZOL reagent (Invitrogen) according to the manufacturer's
instructions. A 32P-labeled antisense probe corresponding to
HPV18 nt. 214 to 567 was synthesized from plasmid pDrive-
HPV18-214–567. Ten micrograms of RNA was hybridized to
105 cpm antisense probe, digested with RNAses and purified
using the RPAIII kit (Ambion) according to the manufacturer's
instructions. Digestion products were separated in a denaturing
urea–polyacrylamide (5%) gel. The dried gel was exposed to
phosphoimager screens, and band intensities were determined
with a FujiBAS1800 and the AIDA software package (Raytest).
Microarray analyses
Total RNAwas isolated from confluent keratinocytes with the
RNeasy Mini kit (Qiagen) according to the manufacturer's
recommendations. Double-stranded cDNA was synthesized
from 5 μg of total RNA from HPV18-transfected keratinocytes
or control keratinocytes using a Superscript choice kit (Invitro-
gen) with a T7-(dT)24 primer incorporating a T7 RNA
polymerase promoter (Metabion). cRNA was prepared and
biotin labeled by in vitro transcription (Enzo Biochemical).
Labeled RNAwas fragmented by incubation at 94 °C for 35 min
in the presence of 40 mM Tris–OAc (pH 8.1), 100 mM KOAc
and 30 mM MgOAc. Labeled, fragmented cRNA (15 μg) was
hybridized for 16 h at 45 °C to a HG-U133A human genome
array (Affymetrix). After hybridization, gene chips were
automatically washed and stained with streptavidin–phycoery-
thrin using a fluidics station. The probe arrays were scanned at 3-
μm resolution using a Genechip System confocal scanner made
for Affymetrix by Agilent. After scanning, the images were
subjected to visual inspection and analyzed using the MAS 5
algorithm (Affymetrix). All chips were scaled to an average
signal value of 150 to enable comparison between individual
arrays. Comparisons were done between “WT” and “control”,
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each condition, four independent biological replicates were
processed and hybridized. To compare expression differences
between groups, cross-comparisons between all four replicates
of the experimental and baseline arrays were carried out using
the Affymetrix default values for detection and change call
statistics in the Micro DB 3.0 Software (Affymetrix). Data
Mining Tool 3.1 software (Affymetrix) was used to filter the
resulting 16 individual comparisons for transcripts that had both
‘Present’ and ‘Increase’ calls in at least 13 out of 16 comparisons
(81%). For these transcripts, the average signal log ratio (SLR)
was calculated and transcripts with an SLR of more than 1 (∼2-
fold change) were called “upregulated”. Accordingly, transcripts
that displayed at least 13 out of 16 ‘Decrease’ calls and an SLR of
−1 were dubbed “downregulated”. Here, transcripts were not
filtered for the detection call. Functional annotation of the
resulting list of probe set IDs was performed using the NetAFFX
analysis center https://www.affymetrix.com/analysis/netaffx/
index.affx).
Western blotting
Total cell extracts were prepared by resuspending pelleted
cells in SDS–lysis buffer. Viscosity of the lysates was reduced
by sonification. Equal volumes were separated on SDS-PAGE
gels (1 mm thickness, 9-well comb) and transferred to
nitrocellulose membranes. Membranes were blocked by
incubation in TBS–0.1% Tween-20–5% nonfat dry milk.
Then, antibodies directed against α-tubulin (Oncogene; Ab-1,
dilution 1:1000), CDC2 (Santa Cruz; sc-8395; dilution 1:1000),
CDKN2A(p16) (PharMingen International; G175-405; dilution
1:1500), MCM7 (Santa Cruz; sc-9966; dilution 1:1000) or
STAT1 (Santa Cruz; sc-346; dilution 1:1500) in TBS–0.1%
Tween-20–5% nonfat dry milk were added. Bound antibodies
were detected with anti-rabbit or mouse antibodies conjugated
to horseradish peroxidase and SuperSignal West Dura or Femto
reagent (Perbio). Chemiluminescent signals were detected with
a FluorSMax Imaging system (Biorad) and quantitated with the
Quantity One software package (Biorad). Care was taken that
the signals were in the linear range.
Acknowledgments
This work was funded by a grant from the Wilhelm-Sander-
Stiftung to F.S. (2001-081-1).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.virol.2006.05.030.
References
Alazawi, W., Pett, M., Arch, B., Scott, L., Freeman, T., Stanley, M.A., Coleman,
N., 2002. Changes in cervical keratinocyte gene expression associated with
integration of human papillomavirus 16. Cancer Res. 62 (23), 6959–6965.
Banno, T., Gazel, A., Blumenberg, M., 2005. Pathway-specific profilingidentifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated
genes in epidermal keratinocytes. J. Biol. Chem. 280 (19), 18973–18980.
Barnard, P., McMillan, N.A., 1999. The human papillomavirus E7 oncoprotein
abrogates signalingmediatedby interferon-alpha.Virology259 (2), 305–313.
Blachon, S., Demeret, C., 2003. The regulatory E2 proteins of human genital
papillomaviruses are pro-apoptotic. Biochimie 85 (8), 813–819.
Bouvard, V., Storey, A., Pim, D., Banks, L., 1994. Characterization of the human
papillomavirus E2 protein: evidence of trans-activation and trans-repression
in cervical keratinocytes. EMBO J. 13 (22), 5451–5459.
Cam, H., Balciunaite, E., Blais, A., Spektor, A., Scarpulla, R.C., Young, R.,
Kluger, Y., Dynlacht, B.D., 2004. A common set of gene regulatory networks
links metabolism and growth inhibition. Mol. Cell 16 (3), 399–411.
Chang, Y.E., Laimins, L.A., 2000. Microarray analysis identifies interferon-
inducible genes and Stat-1 as major transcriptional targets of human
papillomavirus type 31. J. Virol. 74 (9), 4174–4182.
Chin, K.C., Cresswell, P., 2001. Viperin (cig5), an IFN-inducible antiviral
protein directly induced by human cytomegalovirus. Proc. Natl. Acad. Sci.
U.S.A. 98 (26), 15125–15130.
Chung, C.H., Bernard, P.S., Perou, C.M., 2002. Molecular portraits and the
family tree of cancer. Nat. Genet. 32, 533–540.
Cogliano, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F.,
2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6 (4), 204.
Corden, S.A., Sant-Cassia, L.J., Easton, A.J., Morris, A.G., 1999. The integration
of HPV-18 DNA in cervical carcinoma. Mol. Pathol. 52 (5), 275–282.
Cullen, A.P., Reid, R., Campion, M., Lorincz, A.T., 1991. Analysis of the
physical state of different human papillomavirus DNAs in intraepithelial and
invasive cervical neoplasm. J. Virol. 65 (2), 606–612.
Davy, C.E., Jackson, D.J., Wang, Q., Raj, K., Masterson, P.J., Fenner, N.F.,
Southern, S., Cuthill, S., Millar, J.B., Doorbar, J., 2002. Identification of a G
(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type
16. J. Virol. 76 (19), 9806–9818.
Der, S.D., Zhou, A., Williams, B.R., Silverman, R.H., 1998. Identification of
genes differentially regulated by interferon alpha, beta, or gamma using
oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 95 (26), 15623–15628.
Durst, M., Kleinheinz, A., Hotz, M., Gissman, L., 1985. The physical state of
human papillomavirus type 16 DNA in benign and malignant genital
tumours. J. Gen. Virol. 66 (Pt. 7), 1515–1522.
Frattini, M.G., Lim, H.B., Laimins, L.A., 1996. In vitro synthesis of oncogenic
human papillomaviruses requires episomal genomes for differentiation-
dependent late expression. Proc. Natl. Acad. Sci. U.S.A. 93 (7), 3062–3067.
Frattini, M.G., Lim, H.B., Doorbar, J., Laimins, L.A., 1997. Induction of human
papillomavirus type 18 late gene expression and genomic amplification in
organotypic cultures from transfected DNA templates. J. Virol. 71 (9),
7068–7072.
Fu, B., Quintero, J., Baker, C.C., 2003. Keratinocyte growth conditions
modulate telomerase expression, senescence, and immortalization by human
papillomavirus type 16 E6 and E7 oncogenes. Cancer Res. 63 (22),
7815–7824.
Fuchs, P.G., Girardi, F., Pfister, H., 1989. Human papillomavirus 16 DNA in
cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic
marker for early metastases? Int. J. Cancer 43 (1), 41–44.
Garner-Hamrick, P.A., Fostel, J.M., Chien, W.M., Banerjee, N.S., Chow, L.T.,
Broker, T.R., Fisher, C., 2004. Global effects of human papillomavirus type
18 E6/E7 in an organotypic keratinocyte culture system. J. Virol. 78 (17),
9041–9050.
Havard, L., Delvenne, P., Frare, P., Boniver, J., Giannini, S.L., 2002. Differential
production of cytokines and activation of NF-kappaB in HPV-transformed
keratinocytes. Virology 298 (2), 271–285.
Heinz, S., Haehnel, V., Karaghiosoff, M., Schwarzfischer, L., Muller, M.,
Krause, S.W., Rehli, M., 2003. Species-specific regulation of Toll-like
receptor 3 genes in men and mice. J. Biol. Chem. 278 (24), 21502–21509.
Hinata, K., Gervin, A.M., Jennifer Zhang, Y., Khavari, P.A., 2003. Divergent
gene regulation and growth effects by NF-kappa B in epithelial and
mesenchymal cells of human skin. Oncogene 22 (13), 1955–1964.
Huang, S.M., McCance, D.J., 2002. Down regulation of the interleukin-
8 promoter by human papillomavirus type 16 E6 and E7 through effects on
CREB binding protein/p300 and P/CAF. J. Virol. 76 (17), 8710–8721.
Hudelist, G., Manavi, M., Pischinger, K.I., Watkins-Riedel, T., Singer, C.F.,
209B. Karstensen et al. / Virology 353 (2006) 200–209Kubista, E., Czerwenka, K.F., 2004. Physical state and expression of HPV
DNA in benign and dysplastic cervical tissue: different levels of viral
integration are correlated with lesion grade. Gynecol. Oncol. 92 (3), 873–880.
Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M., Nevins, J.R.,
2001. Role for E2F in control of both DNA replication and mitotic functions
as revealed from DNA microarray analysis. Mol. Cell. Biol. 21 (14),
4684–4699.
Jeon, S., Allen-Hoffmann, B.L., Lambert, P.F., 1995. Integration of human
papillomavirus type 16 into the human genome correlates with a selective
growth advantage of cells. J. Virol. 69 (5), 2989–2997.
Kelley, M.L., Keiger, K.E., Lee, C.J., Huibregtse, J.M., 2005. The global
transcriptional effects of the human papillomavirus E6 protein in cervical
carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J. Virol. 79
(6), 3737–3747.
Kho, P.S., Wang, Z., Zhuang, L., Li, Y., Chew, J.L., Ng, H.H., Liu, E.T., Yu, Q.,
2004. p53-regulated transcriptional program associated with genotoxic
stress-induced apoptosis. J. Biol. Chem. 279 (20), 21183–21192.
Klaes, R., Friedrich, T., Spitkovsky, D., Ridder, R., Rudy, W., Petry, U.,
Dallenbach-Hellweg, G., Schmidt, D., von Knebel Doeberitz, M., 2001.
Overexpression of p16(INK4A) as a specific marker for dysplastic and
neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92 (2), 276–284.
Klingelhutz, A.J., Foster, S.A., McDougall, J.K., 1996. Telomerase activation
by the E6 gene product of human papillomavirus type 16. Nature 380
(6569), 79–82.
Leaman, D.W., Chawla-Sarkar, M., Vyas, K., Reheman, M., Tamai, K., Toji, S.,
Borden, E.C., 2002. Identification of X-linked inhibitor of apoptosis-
associated factor-1 as an interferon-stimulated gene that augments TRAIL
Apo2L-induced apoptosis. J. Biol. Chem. 277 (32), 28504–28511.
Li, S., Labrecque, S., Gauzzi, M.C., Cuddihy, A.R., Wong, A.H., Pellegrini, S.,
Matlashewski, G.J., Koromilas, A.E., 1999. The human papilloma virus
(HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-
STAT activation by interferon-alpha. Oncogene 18 (42), 5727–5737.
Markey, M.P., Angus, S.P., Strobeck, M.W., Williams, S.L., Gunawardena,
R.W., Aronow, B.J., Knudsen, E.S., 2002. Unbiased analysis of RB-
mediated transcriptional repression identifies novel targets and distinctions
from E2F action. Cancer Res. 62 (22), 6587–6597.
Meyers, C., Mayer, T.J., Ozbun, M.A., 1997. Synthesis of infectious human
papillomavirus type 18 in differentiating epithelium transfected with viral
DNA. J. Virol. 71 (10), 7381–7386.
Muller, H., Bracken, A.P., Vernell, R., Moroni, M.C., Christians, F., Grassilli, E.,
Prosperini, E., Vigo, E., Oliner, J.D., Helin, K., 2001. E2Fs regulate the
expression of genes involved in differentiation, development, proliferation,
and apoptosis. Genes Dev. 15 (3), 267–285.
Munger, K., Basile, J.R., Duensing, S., Eichten, A., Gonzalez, S.L., Grace, M.,
Zacny, V.L., 2001. Biological activities and molecular targets of the human
papillomavirus E7 oncoprotein. Oncogene 20 (54), 7888–7898.
Munoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah,
K.V., Snijders, P.J., Meijer, C.J., 2003. Epidemiologic classification of
human papillomavirus types associated with cervical cancer. N. Engl. J.
Med. 348 (6), 518–527.
Nakahara, T., Nishimura, A., Tanaka, M., Ueno, T., Ishimoto, A., Sakai, H.,
2002. Modulation of the cell division cycle by human papillomavirus type
18 E4. J. Virol. 76 (21), 10914–10920.
Nees, M., Geoghegan, J.M., Hyman, T., Frank, S., Miller, L., Woodworth, C.D.,
2001. Papillomavirus type 16 oncogenes downregulate expression of
interferon-responsive genes and upregulate proliferation-associated and
NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75 (9),
4283–4296.
Pahl, H.L., 1999. Activators and target genes of Rel/NF-kappaB transcription
factors. Oncogene 18 (49), 6853–6866.
Patel, D., Huang, S.M., Baglia, L.A., McCance, D.J., 1999. The E6 protein of
human papillomavirus type 16 binds to and inhibits co-activation by CBP
and p300. EMBO J. 18 (18), 5061–5072.
Pater, M.M., Pater, A., 1985. Human papillomavirus types 16 and 18 sequences
in carcinoma cell lines of the cervix. Virology 145 (2), 313–318.Perea, S.E., Massimi, P., Banks, L., 2000. Human papillomavirus type 16 E7
impairs the activation of the interferon regulatory factor-1. Int. J. Mol. Med.
5 (6), 661–666.
Pirami, L., Giache, V., Becciolini, A., 1997. Analysis of HPV16, 18, 31, and 35
DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin.
Pathol. 50 (7), 600–604.
Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R.A.,
Dynlacht, B.D., 2002. E2F integrates cell cycle progression with DNA
repair, replication, and G(2)/M checkpoints. Genes Dev. 16 (2), 245–256.
Ronco, L.V., Karpova, A.Y., Vidal, M., Howley, P.M., 1998. Human
papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3
and inhibits its transcriptional activity. Genes Dev. 12 (13), 2061–2072.
Ruutu, M., Peitsaro, P., Johansson, B., Syrjanen, S., 2002. Transcriptional
profiling of a human papillomavirus 33-positive squamous epithelial cell
line which acquired a selective growth advantage after viral integration. Int.
J. Cancer 100 (3), 318–326.
Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., Howley, P.M.,
1990. The E6 oncoprotein encoded by human papillomavirus types 16 and
18 promotes the degradation of p53. Cell 63 (6), 1129–1136.
Schneider-Gadicke, A., Schwarz, E., 1986. Different human cervical carcinoma
cell lines show similar transcription patterns of human papillomavirus type
18 early genes. EMBO J. 5 (9), 2285–2292.
Schwarz, E., Freese, U.K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau,
A., zur Hausen, H., 1985. Structure and transcription of human papilloma-
virus sequences in cervical carcinoma cells. Nature 314 (6006), 111–114.
Semizarov, D., Kroeger, P., Fesik, S., 2004. siRNA-mediated gene silencing: a
global genome view. Nucleic Acids Res. 32 (13), 3836–3845.
Shirasawa, H., Tomita, Y., Fuse, A., Yamamoto, T., Tanzawa, H., Sekiya, S.,
Takamizawa, H., Simizu, B., 1989. Structure and expression of an integrated
human papillomavirus type 16 genome amplified in a cervical carcinoma
cell line. J. Gen. Virol. 70 (Pt. 7), 1913–1919.
Spitkovsky, D., Hehner, S.P., Hofmann, T.G., Moller, A., Schmitz, M.L., 2002.
The human papillomavirus oncoprotein E7 attenuates NF-kappa B
activation by targeting the Ikappa B kinase complex. J. Biol. Chem. 277
(28), 25576–25582.
Sprague, D.L., Phillips, S.L., Mitchell, C.J., Berger, K.L., Lace, M., Turek, L.P.,
Klingelhutz, A.J., 2002. Telomerase activation in cervical keratinocytes
containing stably replicating human papillomavirus type 16 episomes.
Virology 301 (2), 247–254.
Stubenrauch, F., Hummel, M., Iftner, T., Laimins, L.A., 2000. The E8E2C
protein, a negative regulator of viral transcription and replication, is required
for extrachromosomal maintenance of human papillomavirus type 31 in
keratinocytes. J. Virol. 74 (3), 1178–1186.
Vernell, R., Helin, K., Muller, H., 2003. Identification of target genes of the
p16INK4A-pRB-E2F pathway. J. Biol. Chem. 278 (46), 46124–46137.
Wei, C.L., Wu, Q., Vega, V.B., Chiu, K.P., Ng, P., Zhang, T., Shahab, A., Yong,
H.C., Fu, Y., Weng, Z., Liu, J., Zhao, X.D., Chew, J.L., Lee, Y.L.,
Kuznetsov, V.A., Sung, W.K., Miller, L.D., Lim, B., Liu, E.T., Yu, Q., Ng,
H.H., Ruan, Y., 2006. A global map of p53 transcription-factor binding sites
in the human genome. Cell 124 (1), 207–219.
Wentzensen, N., Vinokurova, S., von Knebel Doeberitz, M., 2004. Systematic
review of genomic integration sites of human papillomavirus genomes in
epithelial dysplasia and invasive cancer of the female lower genital tract.
Cancer Res. 64 (11), 3878–3884.
Wilczynski, S.P., Pearlman, L., Walker, J., 1988. Identification of HPV 16 early
genes retained in cervical carcinomas. Virology 166 (2), 624–627.
Wong, Y.F., Cheung, T.H., Tsao, G.S., Lo, K.W., Yim, S.F., Wang, V.W., Heung,
M.M., Chan, S.C., Chan, L.K., Ho, T.W., Wong, K.W., Li, C., Guo, Y.,
Chung, T.K., Smith, D.I., 2006. Genome-wide gene expression profiling of
cervical cancer in Hong Kong women by oligonucleotide microarray. Int. J.
Cancer 118 (10), 2461–2469.
Zhang, N., Ahsan, M.H., Zhu, L., Sambucetti, L.C., Purchio, A.F., West, D.B.,
2005. NF-kappaB and not the MAPK signaling pathway regulates
GADD45beta expression during acute inflammation. J. Biol. Chem. 280
(22), 21400–21408.
